Leveraging Technology to Cut Through the REMS Confusion

The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.

Download White Paper

You may also like:

Blog Post

By now, we’ve all heard: Measles is back. As of May 31, 2019, 7,981 cases of measles had been reported in the U.S in 26 states. Approximately...

View Blog Post
Blog Post

At the recent NCPDP Joint Technical Work Group Meetings, held in Scottsdale in early May, the membership voted to approve three emergency external code list changes. These changes are in response to the Office of the Inspector ...

View Blog Post
Blog Post

For healthcare professionals recently, it seems like nearly every patient, customer at the pharmacy counter, and friend of your mother's has questions about the same thing. CBD oil. CBD...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up